Showing 4431-4440 of 9577 results for "".
- Food Allergy Linked to Early Exposure Through Broken Skinhttps://practicaldermatology.com/news/food-allergy-linked-to-early-exposure-through-broken-skin/2458369/Early exposure to a food allergen through broken skin might prompt the development of food allergy, according to new research in Allergy and Asthma Proceedings. This theory gained further support from a recent study that fo
- US Attorney Announces Charges Against Two Executives Tied to Philidor Pharmacy Schemehttps://practicaldermatology.com/news/us-attorney-announces-charges-against-two-executives-tied-to-philidor-pharmacy-scheme/2458373/The US Attorney’s Office, Southern District of New York has charged two executives in connection with the Philidor Pharmacy scheme that instigated a stock value plunge at Valeant when it was revealed last year. The US Attorney’s office will hold a press conference today to
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability stu
- Eau Thermale Avène Launches #AveneHope for Eczema Awareness Monthhttps://practicaldermatology.com/news/eau-thermale-avne-launches-avenehope-for-eczema-awareness-month/2458411/Eau Thermale Avène is launching their #AveneHope program in recognition of Eczema Awareness Month this October. As part of the program, Avè
- Save the Date: Sept 28th Marks First Ever PsA Awareness Dayhttps://practicaldermatology.com/news/save-the-date-sept-28-is-first-psa-awareness-day/2458433/September 28th marks the first-ever Psoriatic Arthritis (PsA) Awareness Day. Launched by Celgene Corporation and the National Psoriasis Foundation (NPF), PsA Awareness Day is dedicated to education, empowerment, and action for the PsA community. PsA patients can
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now
- Face-Aging App May Encourage Sun-Safe Behaviorhttps://practicaldermatology.com/news/face-aging-app-may-encourage-sun-safe-behavior/2458460/Appealing to their vanity may be the best way to encourage young women to practice sun-safe behaviors, a new study shows. The new research, published in
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),